康寧傑瑞製藥－Ｂ(09966.HK)將於美癌症研究協會年會披露治療癌症藥物臨床試驗摘要

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康寧傑瑞製藥－Ｂ(09966.HK)將於美癌症研究協會年會披露治療癌症藥物臨床試驗摘要

阿思達克 03-09 09:03

康寧傑瑞製藥－Ｂ(09966.HK)公布，KN046(一種重組人源化PD-L1/CTLA-4雙特異性抗體)聯合KN026(一種HER2靶向雙特異性抗體)用於治療局部晚期不可切除或轉移性HER2陽性實體癌患者的初步安全性及療效的II期臨床試驗結果摘要，已獲准並計劃於即將舉行的2022年美國癌症研究協會年會(AACR年會)以電子海報形式展示。摘要及電子海報將於4月8日下午1時正(美國東岸時間)公布。

康寧傑瑞製藥-B(09966.HK)

Relevant Stocks

康寧傑瑞製藥-B(09966.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康寧傑瑞製藥－Ｂ(09966.HK)將於美癌症研究協會年會披露治療癌症藥物臨床試驗摘要

Services

About Us

Agreement Statement